Dorzolamide
Contents
Description
Dorzolamide is a carbonic anhydrase inhibitor used topically to reduce intraocular pressure. It is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. In Harboyan syndrome, which presents with congenital hereditary endothelial dystrophy and progressive sensorineural deafness, dorzolamide may be used to manage corneal edema and associated elevated intraocular pressure.
Indications & Therapeutic Use
elevated intraocular pressure, open-angle glaucoma, ocular hypertension, corneal edema management
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Dorzolamide — GNH India
169 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Dorzolamide |
| Brands | 1 brand available |
| Active Ingredient | Dorzolamide hydrochloride |
| Drug Class | elevated intraocular pressure |
| Manufacturer | Merck & Co. |
| Dosage Forms | Ophthalmic solution, 2% |
| Medical Code | S01EC03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 7 countries |